Growth inhibition of human breast carcinoma cells by overexpression of regulator of G-protein signaling 4

被引:13
作者
Park, Hyun-Jung [1 ]
Kim, Seung-Hyun [1 ]
Moon, Dong-Oh [1 ]
机构
[1] Daegu Univ, Dept Biol Educ, 201 Daegudae Ro, Gyongsan 38453, Gyeongsangbuk D, South Korea
关键词
RGS4; G(2)/M cell cycle; breast cancer; HETEROTRIMERIC G-PROTEINS; RGS PROTEINS; COUPLED RECEPTORS; HEART-FAILURE; IN-VITRO; CANCER; DEGRADATION; EXPRESSION; APOPTOSIS; INVASION;
D O I
10.3892/ol.2017.6009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer remains the second largest cause of mortality in women with cancer and does not respond well to conventional therapies. Regulator of G-protein signaling 4 (RGS4) is a GTPase-activating protein of the heterotrimeric Gq and Gi proteins. Altered levels of RGS4 are reportedly linked with several human diseases, including cancer. The present study investigated whether overexpression of RGS4 inhibited the growth of human breast cancer cells. Protein expression was investigated by western blot analysis. Cell viability and apoptosis were analyzed by MTT assay and flow cytometric analysis, respectively. Cell cycle analysis was performed using propidium iodide staining in order to examine the anti-proliferative function of increased RGS4 levels. Next, changes in the expression levels of G(2)/M cell cycle-related proteins were examined. Overexpression of RGS4 led to the upregulation of phosphorylayed (p)-Ser(216) cell division cycle (Cdc)25C and p-Tyr(15) Cdc2. Importantly, MG132-induced proteasome blockade prevented degradation of RGS4. Suppression of proliferation was associated with G(2)/M-phase cell cycle arrest. Furthermore, enhanced endogenous RGS4 protein levels significantly inhibited breast cancer cell growth, which was reversed by a pharmacological inhibitor of RGS4. Taken together, these results suggest that overexpression of RGS4 in human breast cancer cells by molecular means may offer a potential therapeutic approach.
引用
收藏
页码:4357 / 4363
页数:7
相关论文
共 33 条
[1]   N-terminal residues control proteasomal degradation of RGS2, RGS4, and RGS5 in human embryonic kidney 293 cells [J].
Bodenstein, Johannes ;
Sunahara, Roger K. ;
Neubig, Richard R. .
MOLECULAR PHARMACOLOGY, 2007, 71 (04) :1040-1050
[2]   ERK implication in cell cycle regulation [J].
Chambard, Jean-Claude ;
Lefloch, Renaud ;
Pouyssegur, Jacques ;
Lenormand, Philippe .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2007, 1773 (08) :1299-1310
[3]   Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue [J].
Chen, L ;
Madura, F .
CANCER RESEARCH, 2005, 65 (13) :5599-5606
[4]   The great escape: When cancer cells hijack the genes for chemotaxis and motility [J].
Condeelis, J ;
Singer, RH ;
Segall, JE .
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 2005, 21 :695-718
[5]   RGS4 is arginylated and degraded by the N-end rule pathway in vitro [J].
Davydov, IV ;
Varshavsky, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (30) :22931-22941
[6]   G-protein-coupled receptors and cancer [J].
Dorsam, Robert T. ;
Gutkind, J. Silvio .
NATURE REVIEWS CANCER, 2007, 7 (02) :79-94
[7]   Erk1/2 MAP kinases are required for epidermal G2/M progression [J].
Dumesic, Phillip A. ;
Scholl, Florence A. ;
Barragan, Deborah I. ;
Khavari, Paul A. .
JOURNAL OF CELL BIOLOGY, 2009, 185 (03) :409-422
[8]   The Role of Gβγ Subunits in the Organization, Assembly, and Function of GPCR Signaling Complexes [J].
Dupre, Denis J. ;
Robitaille, Melanie ;
Rebois, R. Victor ;
Hebert, Terence E. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2009, 49 :31-56
[9]   Harnessing the genome for characterization of G-protein coupled receptors in cancer pathogenesis [J].
Feigin, Michael E. .
FEBS JOURNAL, 2013, 280 (19) :4729-4738
[10]   THE LIFETIME RISK OF DEVELOPING BREAST-CANCER [J].
FEUER, EJ ;
WUN, LM ;
BORING, CC ;
FLANDERS, WD ;
TIMMEL, MJ ;
TONG, T .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (11) :892-897